Relief Therapeutics Holding AG (RLFTF)

[go_wamu]

The German company AdVita Lifescience GmbH and its business model:

Their mission:
We develop effective products and strategies to improve the therapy and diagnosis of rare lung diseases.

... and their vision
We want to become one of the leading companies for innovative therapies and diagnostics for rare lung diseases in order to actively contribute to the fact that affected patients can breathe freely again.

Among other things developed active ingredients:
A drug with the active ingredient Aviptadil for inhalative/topical therapy.

Aviptadil (vasoactive intestinal peptide (VIP)) is an endogenous peptide that has already been approved for another indication (erectile dysfunction) with an excellent safety profile.

The preclinical for inhalation therapy is available. Studies and case reports show an excellent effectiveness and tolerance of the drug.

Patients with sarcoid and related diseases (e.g. beryllium disease) have already benefited significantly from treatment in off-label use, so that many health insurance companies cover the costs of the therapy.

The simple application takes place with a nebulizer of the latest generation.

AdVita Lifescience AG is sponsoring a phase II study in Switzerland with the title:
"Inhaled Aviptadil for the prevention of COVID-19 related Acute Respiratory Distress Syndrome (ARDS) - a randomized, double-blind, placebo controlled, multi-center trial".

Swissmedic and the responsible ethics committee have approved the protocol for implementation in several Swiss trial centers.
The study medication was manufactured by a Swiss company and the first patients have been included.

The aim of the study is to find out whether COVID-19 patients at high risk of developing ARDS recover faster when treated with inhaled Aviptadil in addition to standard care.

The clearly visible success in the use of the drug in COVID 19 patients shows already how important the further development of this product is for modern human medicine.